Clinical Trial Update: Pembrolizumab (MK-3475) in Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 study of pembrolizumab (MK-3475) in hepatocellular carcinoma (BCLC stages B and C) has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2025-07-15